FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75709
News▼ Bearish
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Litigation over atrazine cancer risk could raise liability and regulatory scrutiny for Syngenta.
Chemical liability litigation is a slow-burn risk
CATALYST TO WATCH
Court rulings or EPA review outcomes
MAIN RISK
Single plaintiff case may not set precedent
FULL DISPATCH
Apostolos Panayiotou alleges that nearly three decades of mixing and spraying atrazine-based herbicides in Los Angeles County led to his cancer diagnosis. Wisner Baum's lawsuit also challenges what Syngenta told applicators outside its EPA-approved product labels. LOS ANGELES, Oct. 12,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Another Healthcare Increase Is Coming. Are Employers Watching the Spending Closely Enough?2026-10-12 12:09 UTC
Another Healthcare Increase Is Coming. Are Employers Watching the Spending Closely Enough?2026-10-12 12:09 UTC
←CORRELATIONshares Healthcare
Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study2026-10-12 10:00 UTC
Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study2026-10-12 10:00 UTC
←CORRELATIONshares Healthcare
New drug shows multiple improvements for people with Parkinson's disease2026-10-12 10:21 UTC
New drug shows multiple improvements for people with Parkinson's disease2026-10-12 10:21 UTC
←CORRELATIONshares Healthcare
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
←CORRELATIONshares Healthcare
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
←CORRELATIONshares Healthcare
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer2026-10-12 10:50 UTC
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer2026-10-12 10:50 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.